Literature DB >> 8473724

Clozapine-lithium combined treatment and agranulocytosis.

A Valevski1, I Modai, M Lahav, A Weizman.   

Abstract

A case report of clozapine-induced agranulocytosis in a patient treated concomitantly with lithium is reported. The possible role of lithium in the mechanism of clozapine myelosuppression is discussed.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8473724     DOI： 10.1097/00004850-199300810-00011

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN： 0268-1315            Impact factor:   1.659


  7 in total

Review 1.  Continuing clozapine treatment despite neutropenia.

Authors:  David Esposito; Frédéric Rouillon; Frédéric Limosin
Journal:  Eur J Clin Pharmacol       Date:  2004-11-30       Impact factor: 2.953

Review 2.  Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.

Authors:  Eromona Whiskey; David Taylor
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

3.  Lithium dosage and leukocyte counts in psychiatric patients.

Authors:  L K Oyewumi; M McKnight; Z Z Cernovsky
Journal:  J Psychiatry Neurosci       Date:  1999-05       Impact factor: 6.186

4.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

5.  Continuing clozapine with granulocyte colony-stimulating factor in patients with neutropenia.

Authors:  Al Aditya Khan; Jake Harvey; Samrat Sengupta
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

6.  Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia.

Authors:  Kristin N Maher; Marcus Tan; Julia W Tossell; Brian Weisinger; Peter Gochman; Rachel Miller; Deanna Greenstein; Gerald P Overman; Judith L Rapoport; Nitin Gogtay
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-03       Impact factor: 2.576

Review 7.  Mask Off? Lithium Augmentation for Clozapine Rechallenge After Neutropenia or Agranulocytosis: Discontinuation Might Be Risky.

Authors:  Mina Boazak; David R Goldsmith; Robert O Cotes
Journal:  Prim Care Companion CNS Disord       Date:  2018-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.